1. White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev. 2000; 21:245–291. PMID:
10857554.
Article
2. Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, Merke DP, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010; 95:4133–4160. PMID:
20823466.
Article
3. White PC, New MI, Dupont B. Structure of human steroid 21-hydroxylase genes. Proc Natl Acad Sci U S A. 1986; 83:5111–5115. PMID:
3487786.
Article
4. Speiser PW, White PC. Congenital adrenal hyperplasia. N Engl J Med. 2003; 349:776–788. PMID:
12930931.
Article
5. Lee HH. Variants of the CYP21A2 and CYP21A1P genes in congenital adrenal hyperplasia. Clin Chim Acta. 2013; 418:37–44. PMID:
23313747.
Article
6. Lee HH, Lee YJ, Chao MC. Comparing the Southern blot method and polymerase chain reaction product analysis for chimeric RCCX detection in CYP21A2 deficiency. Anal Biochem. 2010; 399:293–298. PMID:
19961824.
Article
7. Lee HH, Lee YJ, Lin CY. PCR-based detection of the CYP21 deletion and TNXA/TNXB hybrid in the RCCX module. Genomics. 2004; 83:944–950. PMID:
15081125.
Article
8. New MI, Abraham M, Gonzalez B, Dumic M, Razzaghy-Azar M, Chitayat D, et al. Genotype-phenotype correlation in 1,507 families with congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. Proc Natl Acad Sci U S A. 2013; 110:2611–2616. PMID:
23359698.
Article
9. Krone N, Braun A, Roscher AA, Knorr D, Schwarz HP. Predicting phenotype in steroid 21-hydroxylase deficiency? Comprehensive genotyping in 155 unrelated, well defined patients from southern Germany. J Clin Endocrinol Metab. 2000; 85:1059–1065. PMID:
10720040.
Article
10. Lee HH, Lee YJ, Wang YM, Chao HT, Niu DM, Chao MC, et al. Low frequency of the CYP21A2 deletion in ethnic Chinese (Taiwanese) patients with 21-hydroxylase deficiency. Mol Genet Metab. 2008; 93:450–457. PMID:
18039588.
Article
11. Wedell A. Molecular genetics of congenital adrenal hyperplasia (21-hydroxylase deficiency): implications for diagnosis, prognosis and treatment. Acta Paediatr. 1998; 87:159–164. PMID:
9512201.
Article
12. Marino R, Ramirez P, Galeano J, Perez Garrido N, Rocco C, Ciaccio M, et al. Steroid 21-hydroxylase gene mutational spectrum in 454 Argentinean patients: genotype-phenotype correlation in a large cohort of patients with congenital adrenal hyperplasia. Clin Endocrinol (Oxf). 2011; 75:427–435. PMID:
21609351.
Article
13. Stikkelbroeck NM, Hoefsloot LH, de Wijs IJ, Otten BJ, Hermus AR, Sistermans EA. CYP21 gene mutation analysis in 198 patients with 21-hydroxylase deficiency in The Netherlands: six novel mutations and a specific cluster of four mutations. J Clin Endocrinol Metab. 2003; 88:3852–3859. PMID:
12915679.
Article
14. Ma D, Chen Y, Sun Y, Yang B, Cheng J, Huang M, et al. Molecular analysis of the CYP21A2 gene in Chinese patients with steroid 21-hydroxylase deficiency. Clin Biochem. 2014; 47:455–463. PMID:
24503005.
Article
15. Yoo Y, Chang MS, Lee J, Cho SY, Park SW, Jin D-K, et al. Genotype-phenotype correlation in 27 pediatric patients in congenital adrenal hyperplasia due to 21-hydroxylase deficiency in a single center. Ann Pediatr Endocrinol Metab. 2013; 18:128. PMID:
24904866.
Article
16. Jang JH, Jin DK, Kim JH, Tan HK, Kim JW, Lee SY, et al. Multiplex ligation-dependent probe amplification assay for diagnosis of congenital adrenal hyperplasia. Ann Clin Lab Sci. 2011; 41:44–47. PMID:
21325254.
17. Choi JH, Jin HY, Lee BH, Ko JM, Lee JJ, Kim GH, et al. Clinical phenotype and mutation spectrum of the CYP21A2 gene in patients with steroid 21-hydroxylase deficiency. Exp Clin Endocrinol Diabetes. 2012; 120:23–27. PMID:
22020670.
Article
18. Xu Z, Chen W, Merke DP, McDonnell NB. Comprehensive mutation analysis of the CYP21A2 gene: an efficient multistep approach to the molecular diagnosis of congenital adrenal hyperplasia. J Mol Diagn. 2013; 15:745–753. PMID:
24071710.